GlassScriptPhysician profile
Samir Klapuh
NPI 1295131993
$5,279.11
in general payments reported to CMS, 2019-2025
28 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 91% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $635 · 2022: $534 · 2023: $1,000 · 2024: $1,757 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,110.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $822.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $779.35 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $661.99 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $642.80 | 2021-2025 | Airsupra, Farxiga, Flumist Quadrivalent |
| Lilly USA, LLC | $429.42 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $331.44 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $307.38 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $255.79 | 2023-2025 | |
| Amgen INC. | $158.13 | 2021-2025 | Evenity, Repatha, Otezla |
| Exact Sciences Corporation | $150.48 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $126.41 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $116.85 | 2024-2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $67.51 | 2024 | Inspire |
| Lundbeck LLC | $56.71 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $41.78 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $40.18 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $35.16 | 2025 | |
| Neurocrine Biosciences, INC. | $35.05 | 2025 | |
| Idorsia Pharmaceuticals US INC | $29.90 | 2023 | Quviviq |
| Abbott Laboratories | $28.35 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $28.02 | 2025 | General - Pain Management |
| Teva Pharmaceuticals USA, INC. | $23.62 | 2025 | Uzedy |
| Corcept Therapeutics | $23.19 | 2024 | Korlym |
| Dexcom, INC. | $20.94 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $20.14 | 2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $17.98 | 2021 | |
| Nevro Corp. | $14.74 | 2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Klapuh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.